Riskpilot← Back to searchSign inGet full accessVM Pharma AB
ABActiveOrg 5568812001StockholmActivities of agents involved in the wholesale of other particular products · NACE 4618Est. 20120 employees
Revenue 2024
SEK 2,4M
-21% vs 2023
EBITDA margin
4.7%
+18% vs 2023
Equity ratio
89.3%
Financial strength
Net profit 2024
SEK 119K
+55% vs 2023
| Revenue | SEK 2,4M | -21% |
| EBITDA | SEK 112K | +18% |
| Net profit | SEK 119K | +55% |
| Total assets | SEK 1,1M | +12% |
| Equity | SEK 972K | +14% |
| Employees | 0 | — |
Legal name
VM Pharma AB
Org number
5568812001
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
18 januari 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är marknadsförings- och konsultationstjänster inom läkemedelsbranschen och därmed förenlig verksamhet.
Address
Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 620 | 1 065 | 2 908 | 3 214 | 2 106 | 2 976 | 2 358 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 130 | 161 | 34 | 137 | 48 | 222 | 66 | 76 | 95 | 112 |
| Depreciation & amort. | −0 | −5 | −16 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 130 | 156 | 18 | 137 | 48 | 222 | 66 | 76 | 95 | 112 |
| Net financials | −2 | −1 | −1 | −1 | −1 | — | — | −9 | 1 | 1 |
| Profit before tax | 95 | 115 | 18 | 111 | 78 | 223 | 100 | 108 | 97 | 150 |
| Tax | −23 | −28 | −21 | −25 | −17 | −48 | −21 | −23 | −20 | −31 |
| Net profit | 72 | 87 | −3 | 86 | 61 | 175 | 79 | 85 | 77 | 119 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 550 | 1 848 | 931 | 839 | 654 | 767 | 816 | 936 | 974 | 1 089 |
| Equity | 207 | 294 | 291 | 377 | 439 | 613 | 692 | 777 | 854 | 972 |
| Long-term debt | 900 | 1 051 | 251 | 251 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 367 | 386 | 272 | 68 | 104 | 43 | 47 | 122 | 84 | 116 |
| Total debt | 1 267 | 1 437 | 523 | 319 | 104 | 43 | 47 | 122 | 84 | 116 |
EBITDA margin
4.7%
This company
15.8%
Market median
-70% vs market
20152024
Equity ratio
89.3%
This company
38.2%
Market median
+134% vs market
20152024
Return on equity
12.2%
This company
18.4%
Market median
+34% vs market
20152024
Net profit margin
5.0%
This company
8.1%
Market median
-38% vs market
20152024
Asset turnover
2.17×
This company
1.12×
Market median
+94% vs market
20152024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ES Authorized Recipient of Service | Authorized Recipient of Service | 2022 | — | — |
IM | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
VET MEDIC ENTERPRISES OY | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VET MEDIC ENTERPRISES OY
VM Pharma AB (this company)Board members of VM Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elin Sofie Schäfer | Authorized Recipient of Service | 0 companies |
| Ingrid Maria Frisell Svedin | Audit | 0 companies |
| Mikko Mauritz Suominen | Board of Directors | 0 companies |
| Maarit Kristina Suominen | Deputy Board Member | 0 companies |